partnership engage grants are expected to respond to the objectives of the insight program and the connection program. however, partnership engage grants cannot respond exclusively to the objectives of the connection program.

these grants provide short-term and timely support for partnered research activities that will inform decision-making at a single partner organization from the public, private or not-for-profit sector. the small-scale, stakeholder-driven partnerships supported through partnership engage grants are meant to respond to immediate needs and time constraints facing organizations in non-academic sectors. in addressing an organization-specific need, challenge and/or opportunity, these partnerships let non-academic organizations and postsecondary researchers access each other’s unique knowledge, expertise and capabilities on topics of mutual interest.

sshrc welcomes applications involving indigenous research, as well as those involving research-creation.

the forest sector investment and innovation program provides funding for strategic investments in the forest sector that:

• improve productivity and innovation
• enhance competitiveness
• support new market access
• provide benefits to ontario’s broader forest sector
• strengthen regional economies

the fy21 defense appropriations act provides funding to the department of defense tick-borne disease research program (tbdrp) to support innovative, high-impact tick-borne disease research. as directed by the office of the assistant secretary of defense for health affairs, the defense health agency j9, research and development directorate manages the defense health program (dhp) research, development, test, and evaluation (rdt&e) appropriation. the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp) at the u.s. army medical research and development command (usamrdc). 

the fy21 tbdrp program announcements and general application instructions for the following award mechanisms are posted on the grants.gov website. 

applicants to the fy21 tbdrp funding opportunities should be relevant to one or more of the following focus areas; however an application that proposes research outside of these focus areas is acceptable, as long as the applicant provides strong justification. applicants are particularly encouraged to submit applications addressing the diagnosis and treatment focus areas.

• diagnosis

• development of direct detection diagnostic assay for agents of lyme and/or other tick-borne diseases (tbds).
• diagnostic biomarker panel for lyme disease and/or other tbds that distinguishes tick-borne (tb) infection from other febrile illnesses.
• approaches capable of distinguishing active infection and previous exposure, and/or monitoring response to treatment.
• innovative approaches that provide diagnosis for a single or multiple tb infections.

• treatment

• novel therapeutic strategies for acute and persistent tbds.
• potential treatments designed to mitigate development of long-term sequelae following infection with bacterial, parasitic, or viral tb agents.
• translational approaches that bridge basic biology to the development of potential treatments.

• prevention

• drugs, antibodies, vaccines, or other novel approaches that can be administered and/or utilized prophylactically to prevent human tbd.
• identification, validation, and/or improvement of tick- or reservoir-targeted prevention and control interventions that are safe and non-toxic to non-target species.
• understanding the ecology of understudied tbd vectors and reservoirs with emphasis on how it relates to human risk.

• pathogenesis

• pathogenesis of persistent clinical manifestations associated with lyme disease.
• immune evasion and/or tolerance of tb pathogens (lyme and/or other tbds).
• effects of tick sialome on human infection, immune response, disease progression, and pathogen dissemination.
• tb infections and co-infections (simultaneous or sequential) and their effects on human disease severity, the local and systemic immune response, or pathogen synergy and competition.
• pathogenesis of mammalian meat allergy (allergic response to galactose-alpha-1,3-galactose (alpha-gal)).
• understanding the potential role of maternal-fetal transmission and the ability to prevent tbds by this mode of transmission.

https://cdmrp.army.mil/funding/tbdrp

career development award – preproposal due may 26, 2021

principal investigator (pi):

early-career research scientist, physician scientist, or other qualified clinical scientist, within 10 years of completion of his/her terminal degree (excluding time spent in residency or on family medical leave) at the time of the submission, working to become independent investigators who exhibit a strong desire to pursue careers in tick-borne disease research; time spent as a postdoctoral fellow is not excluded

mentor: independent investigators at or above the level of associate professor (or equivalent); must have a recent (last 5 years), proven funding and publication record in tick-borne disease research. .

the pi and mentor do not need to be located within the same organization.

• to fund early-career investigators to conduct impactful research under the mentorship of an experienced tick-borne disease researcher.
• career development plan is required. plan should be prepared with appropriate guidance from the mentor, should clearly articulate a strategy for acquiring the necessary skills, competence, and expertise to establish a career at the forefront of tick-borne disease research, and should outline how the pi will gain experience in tick-borne disease research. pi’s institution must demonstrate a commitment to the pi through a minimum of 75% protected research time for tick-borne disease research. the application must include clearly stated plans for interactions and communication coordination between the pi and mentor.
• preliminary data is encouraged, but not required.
• clinical trials are not allowed.
• maximum funding of $300k for direct costs (plus indirect costs).
• maximum period of performance is 3 years.

idea development award – preproposal due may 26, 2021

independent investigators at or above the level of assistant professor (or equivalent).

• to fund research that could lead to impactful discoveries or major advancements that will accelerate progress in improving outcomes for individuals affected by lyme diseases and/or other  tick-borne illnesses.
• research should be conceptually innovative, exhibit high levels of creativity, or challenge existing research paradigms.
• applications must describe the short- and long-term impact of the proposed research, as well as the public health burden of the diseases being addressed.
• preliminary data is encouraged, but not required.
• clinical trials are not allowed; human studies/clinical research are permitted.
• preproposal is required; application submission is by invitation only.

• maximum funding of $600k for direct costs (plus indirect costs).
• maximum period of performance is 3 years

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline. all applications must conform to the final program announcements and general application instructions available for electronic downloading from the grants.gov website. the application package containing the required forms for each award mechanism will also be found on grants.gov. a listing of all cdmrp and other usamrdc extramural funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420.  

for email notification when program announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org. for more information about the tbdrp or other cdmrp-administered programs, please visit the cdmrp website (https://cdmrp.army.mil).

point of contact:

cdmrp help desk 
301-682-5507
help@ebrap.org

the fy21 defense appropriations act is anticipated to provide funding to the department of defense arp to support research of exceptional scientific merit and innovation with high impact that focuses on autism spectrum disorders (asd).  as directed by the office of the assistant secretary of defense for health affairs, the defense health agency j9, research and development directorate, manages the defense health program (dhp) research, development, test, and evaluation (rdt&e) appropriation.  the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp) at the u.s. army medical research and development command (usamrdc).

fy21 arp program announcements and general application instructions for the following award mechanisms are posted on the grants.gov website.    

https://cdmrp.army.mil/funding/arp

clinical trial award – preproposal due may 3, 2021

investigators at or above the level of assistant professor (or equivalent) or

nested early-career investigator partnering principal investigator (pi) option: investigators at or above the level of assistant professor (or equivalent) may collaborate on a single application with a young investigator (at the level of postdoctoral fellow up to early-career independent faculty) that meets the following criteria at the application submission deadline date:

• must be in a current postdoctoral training position or have completed postdoctoral training by the application deadline
• is no more than 7 years from the receipt of a terminal degree
  • has the freedom to commit at least 50% time to the project
  • supports research with the potential to have a major impact on the treatment and/or management of autism spectrum disorders (asd).
  • preliminary data relevant to the proposed clinical trial are required.
  • early-career investigator partnering pi option supports the development of young investigators pursuing or wishing to pursue a career in asd clinical trial research.
  • pre-application is required; application submission is by invitation only.
• the maximum allowable funding for the entire period of performance is $1,800,000 for direct costs (plus indirect costs).
• the maximum period of performance is 4 years.

early-career investigator partnering pi option:

• the maximum allowable funding for the entire period of performance is $2,100,000 for direct costs (plus indirect costs).
• the maximum period of performance is 4 years.

clinical translational research award – preproposal due may 3, 2021

investigators at or above the level of assistant professor (or equivalent)

• supports early-phase, proof-of-principle translational studies with the potential to have a major impact on the treatment and/or management of asd.
• preliminary data relevant to the proposed project are required.
• pre-application is required; application submission is by invitation only.
• the maximum allowable funding for the entire period of performance is $600,000 for direct costs (plus indirect costs).
• the maximum period of performance is 3 years.

idea development award – preproposal due may 3, 2021

investigators at or above the level of assistant professor (or equivalent)

• multiple pi option:  
  up to two investigators may collaborate on a single application, each of whom will be recognized as a pi and receive a separate award.
• supports the development of innovative, high-impact ideas that advance the understanding of asd and ultimately lead to improved outcomes.
• preliminary data are required.
• multiple pi option: up to two investigators may collaborate on a single application, each of whom will be recognized as a pi and receive a separate award.
• pre-application is required; application submission is by invitation only.
• the maximum allowable funding for the entire period of performance is $550,000 for direct costs (plus indirect costs).
• for multiple pis, the combined funding for all pis for the entire period of performance may not exceed $550,000 in direct costs (plus indirect costs).
• the maximum period of performance is 3 years.

career development award – preproposal due may 3, 2021

independent investigators at or below the level of assistant professor (or equivalent) or

established independent investigators in an area other than asd at or above the level of assistant professor (or equivalent) and seeking to transition to a career in asd, thereby bringing their expertise to the field

investigators must not have received a career development award (or equivalent) previously from any program within the cdmrp.

investigators must not have received more than $300,000 in total direct costs for previous or concurrent asd research as a principal investigator of one or more federally or privately funded, non-mentored, peer-reviewed grants.

• supports early-career, independent investigators and/or the transition of established investigators from other research fields to conduct:

○         innovative, high-impact ideas or

○         early-phase, proof-of-principle clinical trials with the potential to have a major impact on asd.

• preliminary data relevant to the proposed project are required.
• pre-application is required; application submission is by invitation only.
• the maximum allowable funding for the entire period of performance is $500,000 for direct costs (plus indirect costs).
• the maximum period of performance is 3 years.

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final program announcements and general application instructions available for electronic downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp and other usamrdc extramural funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420.

for email notification when program announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about the arp or other cdmrp-administered programs, please visit the cdmrp website (https://cdmrp.army.mil).

point of contact:

cdmrp help desk 
301-682-5507 
help@ebrap.org

in this call for applications, we seek to support hypothesis-driven, mechanistic research projects that explore the role played by inflammatory and immune processes in neural development and their effects on the pathophysiology of neurodevelopmental disorders (ndds). our long-term vision is that discoveries made possible by this rfa could lead to the development of mechanism-based interventions that address the fundamental molecular and physiological features that underlie neurodevelopmental conditions.

canada’s international development research centre (idrc) is pleased to announce a new funding opportunity to advance gender analysis and women’s leadership in science, technology, engineering, and mathematics (stem) fields through the gender in stem research initiative.

in the last decade, pioneering work by a number of scholars and organizations around the world has increased awareness of the importance of a more inclusive approach to science, in particular one that integrates women as scientists and users of science, and that recognizes gender analysis as integral to high-quality research and innovation. several initiatives have been launched in response, and some advances have been made. nonetheless we continue to observe twin deficits in women’s representation as leaders in science — notably, in natural sciences, and engineering and maths — and in the integration of gender analysis[1] in these fields. this requires a redoubling of efforts to deepen understanding about the twin gender deficits in stem and propose evidence-based strategies for how higher education and science systems can respond.

this initiative, therefore, will support university-led consortia to expand and deepen scholarship in low- and middle-income countries (lmics), particularly in africa, on the challenges and opportunities that women scientists experience in stem fields and on the importance of gender analysis in stem research. the initiative will increase localized evidence on the key factors that constrain or support women scientists and gender analysis in stem at different levels and in different stem domains, on actual or potential strategies (structures, programs and policies) to address these, and on lessons learned at the level of universities and responsible ministries, nationally and regionally. through research, consortia will be expected to identify innovative approaches that increase the capacity of universities and other higher-education institutions to be more inclusive of women and gender analysis in stem. the ultimate objective is to increase the contribution of science to gender equality.

expressions of interest (eois) are invited from research consortia that bring together the range of multi-disciplinary and sectoral perspectives, capacities, and contributions needed to undertake gender in stem research in line with the objectives, outcomes, and themes of this funding opportunity, as set out below.

eligibility considerations: applications are eligible from consortia involving at least two public universities based in at least two eligible lmics. consortia may also involve researchers based at other institutions in these and other countries, and other stakeholders, as appropriate. consistent with the focus of the call, we expect women scientists to play a leading role in the consortia as established and emerging researchers.  

geographic focus: africa, asia, latin america and the caribbean. up to eight consortia may be funded, half being in africa.

duration of research grants: 36 months

budget: ca$1 million to ca$1.25 million per research consortium; a total of ca$8 million is available for this call. 

canada’s international development research centre (idrc) is pleased to announce a new funding opportunity, implemented through its sustainable inclusive economies division. this call for expressions of interest aims to advance the generation and use of context-specific evidence that can contribute to women’s economic empowerment in the global south in the context of responses in lower-income countries to the covid-19 pandemic and the growing climate crisis.

the call will support solutions-oriented, local research and evidence that help address the specific and systemic barriers women face during and following the covid-19 pandemic, and in accessing opportunities that arise in new low-carbon economic activities. the call will address new barriers that have arisen during the pandemic, the continued disproportionate burden of unpaid care work and gendered social norms, and ways to support and scale women-led initiatives that promote sustainable recovery.

the call will support projects with a clear plan for how the results of the research are to be used by policy-makers, private-sector actors, and women-led and other organizations who are well positioned to advance women’s economic empowerment at scale. proposed projects must take place, and be carried out, by organizations based in low- and lower-middle-income countries in africa, latin america, the caribbean, south and south-east asia, and the middle east.

the call will support collaborative projects involving research organizations, policy-makers, private-sector actors, non-profit and grassroot organizations, and/or other key actors, including in different countries.

this call for expressions of interest (eoi) invites qualifying organizations to submit a short proposal that follows the guidance in this document.

the following services of the contractor are required: to conduct an observational study of the thermoregulatory, cardiovascular, and perceptual implications of varying soft armour torso coverage during physical activity under controlled environmental conditions.

he fy21 defense appropriations act provides funding to the department of defense gulf war illness research program (gwirp) to support research addressing gulf war illness treatment, diagnosis and pathobiology underlying symptoms of disease.  as directed by the office of the assistant secretary of defense for health affairs, the defense health agency j9, research and development directorate manages the defense health program (dhp) research, development, test, and evaluation (rdt&e) appropriation.  the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp) at the u.s. army medical research and development command (usamrdc).

the fy21 gwirp program announcements and general application instructions for the following award mechanisms are posted on the grants.gov website.   

applications submitted to the fy21 gwirp must address one or more of the following overarching challenges:

• treatments:  eliminate the health consequences associated with gulf war illness (gwi) and/or revolutionize treatment
• diagnosis:  better define and diagnose gwi
• subtyping:  distinguish subtypes to better target treatments; or monitor therapy; or identify severity of gwi; or why gwi is worse for some veterans than for others
• determinants:  identify and validate determinants of gwi, latency, and impacts on organs and systems
• consequences:  determine whether gwi alters risk for developing neurological conditions, cancers, or other serious conditions; or whether gwi alters outcomes of other infections/diseases
• communicate & educate:  help veterans, their caregivers, and clinicians communicate effectively about gwi, its symptoms, and potential treatments

https://cdmrp.army.mil/funding/gwirp

idea award – preproposal due may 7, 2021

independent investigators at all academic levels

• supports high-risk/high-reward research in the earliest stages of development that will contribute to markers or treatments for gulf war illness (gwi).
• emphasis is on impact and innovation; applications must articulate how results will lead to a clinical impact for veterans with gwi, even if a clinical impact is not an immediate outcome.
• preliminary data are not required.
• clinical trials are not allowed.
• submission of a pre-application is required; application submission is by invitation only.
• biorepository contribution options:
• supports additional costs associated with submission of samples and data to the gwirp-supported biorepository resource network
• applicants must submit a biorepository contribution statement providing a detailed accounting of proposed costs and a commitment to work with the gwirp-supported biorepository resources network.
• application to this option is not a requirement for idea award submission.
• maximum funding of $200,000 for direct costs (plus indirect costs)
• maximum funding of $220,000 for direct costs with the biorepository contribution option (plus indirect costs).
• maximum period of performance is 2 years

research advancement award – preproposal due may 7, 2021

independent investigators at all academic levels

• supports applied research in gwi aimed at continued expansion and validation of markers and treatments that are supported evidence in the gwi field. 
• preliminary data in the field of gwi and other supporting information is required.
• applications must articulate how results will lead to a clinical impact for veterans with gwi, even if a clinical impact is not an immediate outcome.
• clinical trials are not allowed.
• submission of a pre-application is required; application submission is by invitation only.
• biorepository contribution option:
• supports additional costs associated with submission of samples and data to the gwirp-supported biorepository resource network.
• applicants must submit a biorepository contributions statement providing a detailed accounting of proposed costs and a commitment to work with the gwirp-supported biorepository resource network
• application to this option is not a requirement for research advancement award submission.
• maximum funding of $600,000 for direct costs (plus indirect costs)
• maximum funding of $620,000 for direct costs with the biorepository contribution option (plus indirect costs)
• maximum period of performance is 3 years

clinical evaluation award – preproposal due may 7, 2021

independent investigators at all academic levels

• supports translation of validated gwi research, including qualified and replicated preclinical findings, to a gulf war veteran population.
• statistically powered biomarker trials with the potential to validate use of biomarkers as clinical endpoints or proof-of-concept intervention trials (e.g., pilot, first in human, phase i-iia) are encouraged under this funding opportunity.
• preliminary data are required.
• funding for this award mechanism must support research in a gulf war veteran population.  proof of availability and access to necessary cohort(s) and/or critical regents must be provided.
• submission of a pre-application is required application submission is by invitation only.
• biorepository contribution option:
• supports additional costs associated with submission of samples and data to the gwirp-supported biorepository resource network.
• applicants must submit a biorepository contribution statement providing a detailed accounting of proposed costs and a commitment to work with the gwirp-supported biorepository resource network.
• application to this option is not a requirement for clinical evaluation award submission.
• clinical consortium collaboration option:
• supports additional costs associated with collaboration with the gwirp-support gulf war illness clinical trials and interventions consortium (gwictic).
• applicants must submit a clinical consortium collaboration statement providing a detailed accounting of proposed costs and clearly articulating the qualifications of the research team and institutions to participate as a new clinical research site in the consortium.
• application to this option is not a requirement for clinical evaluation award submission.
• pre-application is required; full application submission is by invitation only.
• maximum funding of $1,500,000 for direct costs (plus indirect costs)
• maximum funding of $1,520,000 for direct costs with the biorepository contribution option (plus indirect costs).
  • maximum funding of $1,700,000 for direct costs with the clinical consortium collaboration option (plus indirect costs)
  • maximum period of performance is 3 years

therapeutic/biomarker trial award – preproposal due may 7, 2021

independent investigators at all academic levels

• supports large-scale, pivotal (phase iib or iii) trials that revolutionize the clinical management of gwi.
• proposed research should lead to an approach that is fundamentally better than interventions already approved or in clinical development.
• objective biomarkers to measure the biological effect of an investigational therapeutic or predictive/cohort-selective biomarkers that indicate whether a specific therapy will be effective in an individual gulf war veteran or gulf war veteran subgroup must be included in the trial design.
• investigators must have experience in successfully leading large-scale projects and demonstrated the ability to implement a clinical project successfully.
• funding must be used to support a clinical trial.
• proposal submission is required: application submission is by invitation only.
• biorepository contribution option:
• supports additional costs associated with submission of samples and data to the gwirp-supported biorepository resource network
• applicants must submit a biorepository contribution statement providing a detailed accounting of proposed costs and a commitment to work with the gwirp-supported biorepository resource network.
• application to this option is not a requirement for therapeutic/biomarker trial award submission.
• clinical consortium collaborative option:
• supports additional costs associated with collaboration with the gwirp-supported gulf war illness clinical trials and interventions consortium (gwictic).
• applicants must submit a clinical consortium collaborative statement providing a detailed accounting of proposed costs and clearly articulates the qualifications of the research team and institution to participate as a new clinical research site in the consortium.
• application to this option is not a requirement for therapeutic/biomarker trial award submission.
  • maximum funding of $5,000,000 for direct costs (plus indirect costs)
  • maximum funding of $5,020,000 for direct costs with the biorepository contribution option (plus indirect costs).
  • maximum funding of $5,500,000 for direct costs with the clinical consortium collaboration option (plus indirect costs).
  • maximum period of performance is 3 years

new investigator award – preproposal due may 7, 2021

pis may apply under one of the following three eligibility categories:

transitioning postdoctoral fellow:  senior postdoctoral fellows with at least 3 years of postdoctoral training

early-career investigator:  independent investigators within 5 years of last training position

new gwi researcher:  established independent investigators who have received less than $300,000 in federally funded, non-mentored gwi research

• encourages applications from early-stage and established investigators new to the field of gwi research.
• previous experience in gwi research is not required; however, collaborations with experienced gwi researchers is strongly encouraged.
• preliminary data are not required.
• clinical trials are not allowed.
• preproposal submission is required; application submission is by invitation only.
• biorepository contribution option:
• supports additional costs associated with submission of samples and data to the gwirp-supported biorepository resource network.
• applicants must submit a biorepository contribution statement providing a detailed accounting of proposed costs and a commitment to work with the gwirp-supported biorepository resource network.
• application to this option is not a requirement for new investigator award submission.
  • maximum funding of $500,000 for direct costs (plus indirect costs)
  • maximum funding of $520,000 for direct costs with the biorepository contribution option (plus indirect costs)
  • the maximum period of performance is 3 years

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final program announcements and general application instructions available for electronic downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp and other usamrdc extramural funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420. 

for email notification when program announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about the gwirp or other cdmrp-administered programs, please visit the cdmrp website (https://cdmrp.army.mil).

point of contact:

cdmrp help desk 
301-682-5507 
help@ebrap.org